Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pan-KRAS inhibitor

A single inhibitor for all KRAS mutations

Nature Cancer volume 4, pages 1060–1062 (2023)Cite this article

Subjects

The recent design of mutation-selective KRAS inhibitors has led to US Food and Drug Administration approval of two inhibitors of KRAS(G12C), sotorasib and adagrasib. A study published in Nature reports the development of a first-in-class pan-KRAS-selective inhibitor. Here we comment on the current status of KRAS-targeting approaches.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Classes of KRAS inhibitors.

References

  1. Ryan, M. B. & Corcoran, R. B. Nat. Rev. Clin. Oncol. 15, 709–720 (2018).

    Article  CAS  PubMed  Google Scholar 

  2. Janne, P. A. et al. N. Engl. J. Med. 387, 120–131 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Skoulidis, F. et al. N. Engl. J. Med. 384, 2371–2381 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Wang, X. et al. J. Med. Chem. 65, 3123–3133 (2022).

    Article  CAS  PubMed  Google Scholar 

  5. Zhang, Z., Guiley, K. Z. & Shokat, K. M. Nat. Chem. Biol. 18, 1177–1183 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zhang, Z., Morstein, J., Ecker, A. K., Guiley, K. Z. & Shokat, K. M. J. Am. Chem. Soc. 144, 15916–15921 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M. & Kraut, N. Cancer Discov. 12, 924–937 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kim, D. et al. Nature 619, 160–166 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Awad, M. M. et al. N. Engl. J. Med. 384, 2382–2393 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tanaka, N. et al. Cancer Discov. 11, 1913–1922 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Koltun, E. S. et al. Cancer Res. 82, 3597–3597 (2022).

    Article  Google Scholar 

  12. Ryan, M. B. et al. Cell Rep. 39, 110993 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hunter, J. C. et al. Mol. Cancer Res. 13, 1325–1335 (2015).

    Article  CAS  PubMed  Google Scholar 

  14. Killoran, R. C. & Smith, M. J. J. Biol. Chem. 294, 9937–9948 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lito, P., Solomon, M., Li, L. S., Hansen, R. & Rosen, N. Science 351, 604–608 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

    Ryan B. Corcoran

Authors
  1. Ryan B. Corcoran
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Ryan B. Corcoran.

Ethics declarations

Competing interests

R.B.C. has received consulting or speaking fees from Abbvie, Amgen, Array Biopharma/Pfizer, Asana Biosciences, Astex Pharmaceuticals, Astellas, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Cogent Biosciences, Daiichi-Sankyo Elicio, Erasca, Fog Pharma, Genentech, Guardant Health, Ipsen, Kinnate Biopharma, LOXO, Merrimack, Mirati Therapeutics, Natera, Navire, Nested Therapeutics, N-of-one/Qiagen, Novartis, nRichDx, Remix Therapeutics, Revolution Medicines, Roche, Syndax, Tango Therapeutics, Taiho and Theonys; holds equity in Avidity Biosciences, C4 Therapeutics, Cogent Biosciences, Erasca, Kinnate Biopharma, Interline Therapeutics, Nested Therapeutics, nRichDx, Remix Therapeutics, Revolution Medicines and Theonys; is a co-founder, equity holder and board member of Alterome Therapeutics and Sidewinder Therapeutics; and has received research funding from Asana, AstraZeneca, Invitae, Lilly, Novartis and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Corcoran, R.B. A single inhibitor for all KRAS mutations. Nat Cancer 4, 1060–1062 (2023). https://doi.org/10.1038/s43018-023-00615-x

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-023-00615-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research